$T2 Biosystems (TTOO.US)$T2 Biosystems Announces Plans to License Its Proprietary Technology to Expand Its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens GlobeNewswire· 6 mins ago Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream LEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the "Company"), a leader in the rapid detection o...
$Tonix Pharmaceuticals (TNXP.US)$ Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers Positive Fast Track designation received from FDA, expediting the review process Significant positive results in Phase 3 RESILIENT trial with p-value of 0.00005 Addressing $2.8 billion market expected to grow to $4.13 billion by 2032 Potential to be first new fibromyalgia drug in over 15 years Negative None.
$Tonix Pharmaceuticals (TNXP.US)$ Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers Monday, 9th December at 7:30 am This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowle...
$Tonix Pharmaceuticals (TNXP.US)$On December 6, 2024, Tonix Pharmaceuticals filed a Form S-8 Registration Statement with the SEC to register an additional 289,862 shares of common stock. These shares are available under the company's Amended and Restated 2020 Stock Incentive Plan, due to the Evergreen Provision, which allows for an automatic annual increase in shares. The additional shares are of the same class as the previously registered 76,479 shares under the 2020 Plan. This registration aim...
$LumiraDx (LMDXF.US)$currently under negotiations according to both SOFI & SHWABB. We have 1.2B in assets$Poseida Therapeutics (PSTX.US)$had 250m in assets & 200m in liabilities got a banger of a deal at 1.5B evaluation from$ROCHE HOLDING AG (RHHBY.US)$so even without overhang we are worth a 1:1 rhhby conversion based on how much of the company Roche got in the deal. That's not including if RonZ has plans for us with ElectraDX or if DNEDX has plans. 👀👀👀 could realistically be looking at 50.00...
72638079
:
NDA acceptance this month, no doubt that this is a gamble, however the profitability on this stock could be massive overnight with the right number of shares
GlobeNewswire· 6 mins ago
Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream
LEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the "Company"), a leader in the rapid detection o...
GeoVax Receives Notice of Allowance for Cancer Vaccine Patent
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers
Positive
Fast Track designation received from FDA, expediting the review process
Significant positive results in Phase 3 RESILIENT trial with p-value of 0.00005
Addressing $2.8 billion market expected to grow to $4.13 billion by 2032
Potential to be first new fibromyalgia drug in over 15 years
Negative
None.
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers
Monday, 9th December at 7:30 am
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowle...
The additional shares are of the same class as the previously registered 76,479 shares under the 2020 Plan. This registration aim...
No comment yet